NCT02237729 - A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07)) | Biotech Hunter

Enrollment

362

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Healthy Subjects

Interventions

BIOLOGICAL

PF-06410293

PF-06410293 will be administered as a single 40 mg, subcutaneous dose

BIOLOGICAL

Adalimumab-US

Adalimumab-US will be administered as a single 40 mg, subcutaneous dose

BIOLOGICAL

Adalimumab-EU

Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose

Trial Locations (8)

SeaView Jacksonville, Jacksonville

SeaView Research, Inc., Miami

De La Pedraja Radiology Associates, Coral Gables

SeaView Reseach Screening Office, Miami

SeaView Research, Inc. (Screening Office), Miami

Prism Research, LLC, Saint Paul

Vince & Associates Clinical Research, Inc., Overland Park

Vince & Associates Clinical Research, Inc., Overland Park